[go: up one dir, main page]

CL2008003357A1 - Process for obtaining a solution of human albumin with high capacity of molecule binding comprising a diafiltration, stabilization with nacl and amino acids without the addition of fatty acids, pasteurization and a second diafiltration. - Google Patents

Process for obtaining a solution of human albumin with high capacity of molecule binding comprising a diafiltration, stabilization with nacl and amino acids without the addition of fatty acids, pasteurization and a second diafiltration.

Info

Publication number
CL2008003357A1
CL2008003357A1 CL2008003357A CL2008003357A CL2008003357A1 CL 2008003357 A1 CL2008003357 A1 CL 2008003357A1 CL 2008003357 A CL2008003357 A CL 2008003357A CL 2008003357 A CL2008003357 A CL 2008003357A CL 2008003357 A1 CL2008003357 A1 CL 2008003357A1
Authority
CL
Chile
Prior art keywords
diafiltration
solution
stabilization
obtaining
pasteurization
Prior art date
Application number
CL2008003357A
Other languages
Spanish (es)
Inventor
Debart Pere Ristol
Nieto Juan Ignacio Jorquera
Rierola Monserrat Costa
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of CL2008003357A1 publication Critical patent/CL2008003357A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procedimiento para obtención de solución de albúmina humana, con alta capacidad de enlace de moléculas que comprende una primera diálisis, la estabilización con cloruro de sodio, y uno o varios aminoácidos, el calentamiento de la solución, y una segunda diálisis; uso de la solución de albúmina para terapia de detoxificación.Process for obtaining human albumin solution, with high binding capacity of molecules comprising a first dialysis, stabilization with sodium chloride, and one or several amino acids, heating the solution, and a second dialysis; use of albumin solution for detoxification therapy.

CL2008003357A 2007-11-12 2008-11-11 Process for obtaining a solution of human albumin with high capacity of molecule binding comprising a diafiltration, stabilization with nacl and amino acids without the addition of fatty acids, pasteurization and a second diafiltration. CL2008003357A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702983A ES2294976B1 (en) 2007-11-12 2007-11-12 "HIGH EFFECTIVE HUMAN ALBUMIN OBTAINING PROCEDURE FOR USE IN DETOXIFICATION THERAPY".

Publications (1)

Publication Number Publication Date
CL2008003357A1 true CL2008003357A1 (en) 2011-01-07

Family

ID=39167937

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003357A CL2008003357A1 (en) 2007-11-12 2008-11-11 Process for obtaining a solution of human albumin with high capacity of molecule binding comprising a diafiltration, stabilization with nacl and amino acids without the addition of fatty acids, pasteurization and a second diafiltration.

Country Status (15)

Country Link
US (2) US8088416B2 (en)
EP (1) EP2072056B1 (en)
JP (2) JP2009137947A (en)
CN (1) CN101492493B (en)
AR (1) AR069220A1 (en)
AU (1) AU2008243225B2 (en)
BR (1) BRPI0805167B8 (en)
CA (1) CA2643508C (en)
CL (1) CL2008003357A1 (en)
ES (2) ES2294976B1 (en)
HU (1) HUE026991T2 (en)
MX (1) MX2008014273A (en)
NZ (1) NZ572652A (en)
PL (1) PL2072056T3 (en)
RU (1) RU2424822C2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294976B1 (en) * 2007-11-12 2008-12-16 Grifols, S.A. "HIGH EFFECTIVE HUMAN ALBUMIN OBTAINING PROCEDURE FOR USE IN DETOXIFICATION THERAPY".
JP6247210B2 (en) * 2011-07-05 2017-12-13 アルブミディクス アクティーゼルスカブ Albumin preparation and use
WO2013125932A1 (en) * 2012-02-22 2013-08-29 Даугавпилсский Университет Method for evaluating the structural and functional properties of blood plasma albumin
AU2013205138B2 (en) * 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
CN103087184B (en) * 2013-01-14 2014-04-02 山西康宝生物制品股份有限公司 Method for controlling prekallikrein activator in human serum albumin product
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
ES2524516B1 (en) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Preparation procedure of human albumin with reduced dissolved oxygen level
CN110198952B9 (en) 2016-08-17 2024-05-28 勃林格殷格翰国际公司 Method for preparing highly concentrated liquid formulations containing biomolecules
SI3484502T1 (en) * 2016-08-18 2022-01-31 Alkahest, Inc. Blood plasma fractions as a treatment for age-related cognitive impairment
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12151045B2 (en) 2020-12-28 2024-11-26 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
CH720224B1 (en) * 2023-08-18 2024-05-31 Csl Behring Ag Process for sterile filtration of albumin-containing aqueous solutions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5128727A (en) 1974-09-04 1976-03-11 Canon Kk
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
JP3554796B2 (en) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 Albumin preparation and method for producing the same
FR2672604B1 (en) 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc PROCESS FOR ISOLATING HUMAN ALBUMIN FROM SURNANTANT IV, PARTICULARLY IV-4, OR FRACTION V OF COHN OR OF A SURNANTANT OR THE LIKE FRACTION.
US5368555A (en) * 1992-12-29 1994-11-29 Hepatix, Inc. Organ support system
AUPM388494A0 (en) * 1994-02-16 1994-03-10 Csl Limited Process for removing endotoxins
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
ES2103236B1 (en) * 1996-01-30 1998-04-16 Grifols Grupo Sa THERAPEUTIC HUMAN ALBUMINA WITH LOW CAPACITY FOR FIXING ALUMINUM.
ES2107390B1 (en) 1996-01-30 1998-07-01 Grupo Grifolls S A PROCEDURE FOR THE PREPARATION OF THERAPEUTIC HUMAN ALBUMINA WITH LOW CAPACITY FOR THE FIXATION OF ALUMINUM.
AT403989B (en) * 1996-09-16 1998-07-27 Immuno Ag METHOD FOR PRODUCING A PLASMA PROTEIN-CONTAINING MEDICINAL PRODUCT
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US5919907A (en) * 1997-12-22 1999-07-06 Shanbrom Technologies Llc Preparation and utilization of a novel sterile albumin
DE19831061A1 (en) * 1998-07-10 2000-01-13 Rotkreuzstiftung Zentrallab Reducing aggregate content of protein preparation, especially virus-inactivated therapeutic plasma protein or chemically modified protein preparation
RU2140287C1 (en) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Method of albumin preparing
DE69911438T2 (en) * 1999-06-15 2004-07-01 BBI BioSeq, Inc., Woburn FAST DEEP TEMPERATURE PRESSURE STERILIZATION AND VACCINE PRODUCTION
EP1565207B1 (en) * 2002-11-25 2006-04-12 Octapharma AG Prekallikrein depleted plasma derived albumin fraction
ES2285427T3 (en) 2003-02-13 2007-11-16 Octapharma Ag PROCEDURE FOR PREPARATION OF AN ALBUMIN SOLUTION.
CN1756587A (en) * 2003-03-12 2006-04-05 弗雷泽纽斯卡比德国有限公司 Use of recombinant albumin in dialysis after liver failure
FR2866890B1 (en) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement ALBUMIN PURIFICATION PROCESS COMPRISING A NANOFILTRATION STEP, SOLUTION AND THERAPEUTIC USE COMPOSITION CONTAINING THE SAME
JP2008523829A (en) * 2004-12-22 2008-07-10 ノボザイムス アクティーゼルスカブ Recombinant production of serum albumin
DE102005023155A1 (en) * 2005-05-13 2006-11-16 Albutec Gmbh albumin solution
ES2294976B1 (en) * 2007-11-12 2008-12-16 Grifols, S.A. "HIGH EFFECTIVE HUMAN ALBUMIN OBTAINING PROCEDURE FOR USE IN DETOXIFICATION THERAPY".

Also Published As

Publication number Publication date
US20090181102A1 (en) 2009-07-16
US8088416B2 (en) 2012-01-03
HUE026991T2 (en) 2016-08-29
AU2008243225A1 (en) 2009-05-28
CA2643508A1 (en) 2009-05-12
NZ572652A (en) 2010-03-26
JP2013173767A (en) 2013-09-05
CN101492493B (en) 2013-05-29
ES2564310T3 (en) 2016-03-21
CA2643508C (en) 2013-06-11
MX2008014273A (en) 2009-05-11
US8231599B2 (en) 2012-07-31
JP2009137947A (en) 2009-06-25
ES2294976A1 (en) 2008-04-01
ES2294976B1 (en) 2008-12-16
RU2424822C2 (en) 2011-07-27
EP2072056A1 (en) 2009-06-24
BRPI0805167A2 (en) 2009-07-14
JP5744959B2 (en) 2015-07-08
BRPI0805167B8 (en) 2021-05-25
RU2008144318A (en) 2010-05-20
BRPI0805167B1 (en) 2019-01-02
EP2072056B1 (en) 2016-02-24
PL2072056T3 (en) 2016-06-30
AU2008243225B2 (en) 2011-09-08
CN101492493A (en) 2009-07-29
US20110137283A1 (en) 2011-06-09
AR069220A1 (en) 2010-01-06
HK1129401A1 (en) 2009-11-27

Similar Documents

Publication Publication Date Title
CL2008003357A1 (en) Process for obtaining a solution of human albumin with high capacity of molecule binding comprising a diafiltration, stabilization with nacl and amino acids without the addition of fatty acids, pasteurization and a second diafiltration.
ES2512141T3 (en) Oxintomodulin Peptide Analog
ES2486675T3 (en) Oxintomodulin Peptide Analog
BR112013029409A2 (en) "peptide product comprising peptide covalently linked surfactant, pharmaceutical composition comprising it, as well as use of peptide product in the treatment of condition associated with insulin resistance, cardiovascular disease and diabetes"
CY1121687T1 (en) AMINO ACID SEQUENCES TARGETING ENVELOPE PROTEINS OF AN IOY AND POLYPEPTIDES CONTAINING THEM FOR THE THERAPEUTIC TREATMENT OF VIRAL DISEASES
CY1121632T1 (en) RV2386C TUBERCULOSIS PROTEIN, ITS COMPOSITIONS AND USES
EA200802184A1 (en) PHARMACEUTICAL COMPOSITIONS WITH DPP IV INHIBITORS
ECSP088962A (en) NEW HERBICIDES
CY1118120T1 (en) FIELD-BASED FIELD III COMPOSITIONS, METHODS AND USES OF THESE
BRPI0810096A2 (en) ANTI-EPCAM ANTIBODY AND ITS USES
CO6341637A2 (en) \\\\\\\ "NEW COMPOSITIONS AND METHODS \\\\\\\"
EA200970446A1 (en) CONNECTING WITH ALBUMIN MOLECULES AND THEIR APPLICATION
MX2012002216A (en) NEW ENDOLISINE OBPGPLYS.
EA200870129A1 (en) HUMAN ANTIBODIES AGAINST IL-23, COMPOSITIONS, METHODS AND APPLICATIONS
BR112012006252A2 (en) "crystalline forms of abt-263 and solvates for use in the treatment of bcl-2 protein related diseases".
CY1121628T1 (en) SALTS IT AND METHODS OF USE
MX337358B (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof.
CY1114811T1 (en) NEW FRACTIONS OF PROTEIN MILK AND THEIR USE FOR PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
CL2012003119A1 (en) Pharmaceutical composition for injection that compensates for an aqueous solution of ibuprofen and trometamol, in which the concentration of ibuprofen is between 2 and 6 mg / ml, the concentration of trometamol is between 1.8 and 5.8 mg / ml, and the pH is between 7.0 and 9.5; and its use for the treatment of pain, inflammation or fever.
ATE458819T1 (en) CONJUGATE WITH P21 PROTEIN FOR CANCER TREATMENT
CY1121886T1 (en) PHENYLALANINE-FREE PROTEIN FOR THE TREATMENT OF PKU
BRPI0812026A2 (en) vegf-d mutants and their use
UY30952A1 (en) S, S-DIOXIDE ACID POLYMORPHES 7- [3-CHLORINE-6,11-DIHYDRO-6-METHYDLIBENZO [C, F] [1,2] THIAZEPIN-11-ILAMINO] HEPTANOIC AND METHODS FOR PREPARATION AND USE
BRPI0416105A (en) use of bh4 for the treatment of respiratory disease
WO2015063452A3 (en) Cell transport